US Patent 10,130,580: Claim Scope, Validity Risks, Exclusivity and Generic Entry Analysis

US Patent 10,130,580 protects a specific orally disintegrating tablet architecture combining taste-masked drug particles with rapidly dispersing microgranules. The independent claim is broad as to the active pharmaceutical ingredient but narrow as to coating chemistry, polymer ratio, coating level, dissolution performance, microgranule structure, and dosage form. A product must satisfy every limitation of claim 1 to create literal infringement risk.

The patent is a formulation-platform patent rather than a drug-specific patent. The supplied claims do not identify an active ingredient, approved product, patent family, priority date, terminal disclaimer, patent term adjustment, Orange Book listing, litigation history, or licensing transaction. Those items cannot be established from the claim language alone.

What does US Patent 10,130,580 claim?

Claim 1 requires a pharmaceutical composition containing two physically distinct populations:

Required component	Claim limitation
Taste-masked particles	Drug-containing core particle with a membrane
Membrane chemistry	Ethylcellulose plus an aminoalkyl methacrylate copolymer
Membrane polymer ratio	Water-insoluble polymer to gastrosoluble polymer of about 50/50
Coating level	Membrane thickness stated as about 10% to 30% by weight of the coated particle
Dissolution	At least about 60% drug release after 30 minutes
Dissolution test	USP Apparatus 2, paddles at 50 rpm, 900 mL of 0.1 N HCl, pH 1.2
Microgranules	Rapidly dispersing microgranules averaging no more than 400 micrometers
Microgranule ingredients	A disintegrant plus a sugar alcohol, saccharide, or combination
Ingredient particle size	Each disintegrant and sugar alcohol or saccharide particle averages no more than 30 micrometers
Dosage form	Orally disintegrating tablet

The claim is a combination claim. A formulation using the specified taste-masking coating but lacking the claimed microgranules should not literally meet claim 1. Conversely, an orally disintegrating tablet using the specified microgranules but a different taste-masking system should also fall outside literal claim 1.

How should the independent claim be construed?

Taste-masked particle limitations

The claimed drug-containing core may be a particulate active ingredient or a drug-loaded carrier. The claim does not impose an active-ingredient identity, therapeutic class, dose, or drug-loading percentage.

The membrane must contain both:

Ethylcellulose, the water-insoluble polymer; and
An aminoalkyl methacrylate copolymer, the gastrosoluble polymer.

The wording identifies polymer function as well as polymer identity. A formulation using a different water-insoluble polymer, such as a methacrylate copolymer or cellulose acetate, would have a strong non-infringement position for the literal polymer limitation. A formulation using a different pH-soluble polymer may likewise avoid the aminoalkyl methacrylate requirement.

The approximately 50/50 ratio is a central limitation. It likely refers to the relative weight of ethylcellulose and aminoalkyl methacrylate copolymer in the taste-masking membrane. A formulation materially outside that ratio may avoid literal infringement, although the scope of "about" depends on intrinsic evidence, prosecution history, measurement method, and technical context. A court would likely examine formulation examples and any amendments made during prosecution before assigning a numerical tolerance.

Coating thickness or coating weight

The claim describes membrane thickness as ranging from about 10% to 30% by weight of the coated particle. The terminology is technically imprecise because thickness is normally expressed as a dimensional measurement, while a percentage by weight generally describes coating weight gain:

[ \text{Coating weight percentage} = \frac{\text{membrane weight}}{\text{coated particle weight}} \times 100 ]

The specification may clarify whether the claimed range means membrane weight as a percentage of the final coated particle or weight gain relative to the uncoated core. That distinction affects infringement testing and claim validity.

A formulation with a 9% or 31% coating level could present a design-around position, but measurement error and the meaning of "about" would matter. The safest technical design-around would use a substantially different coating level and document the analytical method.

Dissolution limitation

Claim 1 requires release of at least about 60% of the total drug after 30 minutes under a defined acidic dissolution protocol. This is a functional limitation, but it is tied to a reproducible test framework:

USP Apparatus 2;
Paddle method;
50 rpm;
900 mL;
0.1 N hydrochloric acid;
pH 1.2;
30-minute endpoint.

The test condition limits both infringement analysis and validity analysis. A product that releases 60% in a different medium or under a different apparatus does not automatically satisfy the claim. Analytical laboratories would need to replicate the specified conditions, including temperature, deaeration, sampling, assay method, vessel configuration, and calculation of total drug.

The dissolution limitation also creates a potential enforcement issue. Lot-to-lot variation, coating uniformity, drug particle size, and agglomeration can affect whether a product consistently meets the threshold.

What do the dependent claims add?

Claim	Added limitation	Commercial significance
2	Drug quantity sufficient for oral therapeutic dosing	Broadens practical application but adds little technical limitation
3	Sugar alcohol or saccharide to disintegrant ratio of about 95/5	Narrows microgranule composition
4	Microgranules to taste-masked particles ratio of about 2:1	Narrows the tablet blend
5	Specific disintegrants, including crospovidone, sodium starch glycolate, croscarmellose sodium, and low-substituted hydroxypropylcellulose	Captures common disintegrant choices
6	Crospovidone and mannitol	Establishes a commercially important embodiment
7	Drug-containing core particle size of no more than about 400 micrometers	Adds particle-size control for the drug core
8	Tablet friability of no more than 1%	Adds mechanical-strength performance
9	Disintegration within approximately 60 seconds in saliva	Adds an oral-disintegration performance limitation
10	Mannitol as the sugar alcohol or saccharide	Narrows claim 1 to a common ODT filler
11	Acceptable taste masking after 60 seconds in the oral cavity	Adds a subjective performance limitation
12	Microgranule average size of no more than 300 micrometers	Narrows the 400-micrometer limitation

Claim 3 does not modify the 50/50 ratio of ethylcellulose to aminoalkyl methacrylate copolymer. It addresses a separate ratio: sugar alcohol or saccharide to disintegrant.

Claim 4 appears grammatically incomplete because it states that the ratio "ranges from about 2/1" rather than specifying a range. Its enforceable meaning would depend heavily on the specification and prosecution history.

Claim 11 is potentially vulnerable to indefiniteness because "acceptable taste-masking" is subjective unless the patent provides a defined sensory protocol, panel standard, threshold, or comparative test. Claim 9 is more measurable, but "approximately 60 seconds" still requires interpretation.

How broad is the patent’s practical coverage?

The patent has broad drug coverage but narrow formulation coverage.

Broad elements

No specific active ingredient is required.
No specific therapeutic indication is required.
No fixed dose is required.
No specific manufacturing process is required.
The drug core may potentially encompass multiple particulate forms.
The claim covers an ODT platform applicable to multiple immediate-release drugs.

Narrow elements

Both ethylcellulose and an aminoalkyl methacrylate copolymer are required.
The membrane ratio is about 50/50.
The coating level is about 10% to 30% by weight.
The product must meet the specified acidic dissolution result.
The formulation must contain rapidly dispersing microgranules.
The microgranules require small-particle disintegrant and sugar alcohol or saccharide components.
The final dosage form must be an orally disintegrating tablet.

The combination requirement materially limits the claim. A conventional taste-masked tablet, a standard orally disintegrating tablet, or an ODT using a different coating system would not necessarily fall within the claim.

What formulation design-arounds could reduce infringement risk?

Potential design-around strategies include:

Use a taste-masking membrane without ethylcellulose.
Use ethylcellulose with a gastrosoluble polymer other than an aminoalkyl methacrylate copolymer.
Move the polymer ratio materially away from approximately 50/50.
Use a coating weight outside the claimed range.
Eliminate the rapidly dispersing microgranule population.
Use microgranules with average particle size above 400 micrometers.
Use disintegrant or saccharide particles above 30 micrometers.
Develop a conventional tablet, chewable tablet, capsule, or orally soluble film instead of an ODT.
Use a taste-masking architecture based on matrix embedding, ion exchange, lipid coating, or complexation rather than the claimed dual-polymer membrane.

Each design-around must be assessed against the doctrine of equivalents. A change that preserves the same function, way, and result as the claimed element may still present litigation risk, particularly where the substituted polymer performs the same taste-masking and gastric-release function.

How strong is the patent estate based on the claim set?

The individual claim has commercial value because it combines sensory performance, disintegration, particle engineering, and dissolution requirements. That combination can make the claim difficult to invalidate through a single reference.

The principal validity risks are the following:

Anticipation risk under 35 U.S.C. § 102

An anticipating reference would need to disclose every limitation of claim 1, including the specific polymer pair, approximately 50/50 membrane ratio, coating level, acidic dissolution result, microgranules, particle-size limits, and ODT format. Earlier references disclosing only taste-masked particles or only ODT microgranules would not anticipate the full combination.

Obviousness risk under 35 U.S.C. § 103

The claim may face a stronger obviousness challenge if the prior art separately teaches:

Ethylcellulose and aminoalkyl methacrylate copolymers for taste masking;
50/50 polymer blends;
Mannitol and crospovidone microgranules;
ODT compression;
Particle-size control; and
Rapid dissolution in acidic medium.

The patent holder would likely rely on formulation compatibility, taste performance, tablet strength, rapid disintegration, and dissolution results as evidence of non-obviousness. Unexpected results would be important if the prosecution record contains comparative data.

Written description and enablement risk under 35 U.S.C. § 112

Because claim 1 covers any drug, the specification must support a technically meaningful genus of active ingredients. Enablement risk increases if the disclosure contains only a small number of examples and does not explain how the coating system works across drugs with materially different solubility, dose, particle morphology, and taste profiles.

The lack of a defined test for "acceptable taste-masking" may create an additional section 112(b) issue for claim 11.

What is the Orange Book status of US Patent 10,130,580?

The supplied claims do not identify an active ingredient or approved drug product. Orange Book listing cannot be inferred from the patent number or claim language.

A formulation patent may be submitted for listing if it claims an approved drug product or an approved method of use and satisfies FDA listing requirements. The absence of a named active ingredient makes it impossible to connect these claims to a particular NDA, product, or Orange Book patent entry from the claim text alone. FDA Orange Book listing is product-specific, not a general consequence of patent issuance.[2]

When does US Patent 10,130,580 lose exclusivity?

The grant date does not determine the patent’s expiration date. Under 35 U.S.C. § 154, utility patent term generally runs 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable priority claims.[3]

The claim text does not provide:

Earliest nonprovisional filing date;
Continuation or divisional status;
Patent-term adjustment;
Terminal disclaimer;
Patent-term extension; or
Reissue status.

Accordingly, a precise expiration date cannot be established from the supplied information. The patent’s legal term must be calculated from the USPTO prosecution record.

What Paragraph IV and generic-entry risks exist?

Paragraph IV risk depends on an ANDA applicant’s certification against a listed patent. If the patent is listed for an approved drug, a generic applicant could challenge it by asserting non-infringement, invalidity, or unenforceability under a Paragraph IV certification.

For this claim set, the strongest generic positions would likely involve:

A different taste-masking polymer system;
A materially different polymer ratio;
No microgranules;
Different particle-size distributions;
A non-ODT dosage form; or
Failure to meet the specified dissolution threshold.

A generic applicant using ethylcellulose, an aminoalkyl methacrylate copolymer, approximately equal polymer weights, mannitol-crospovidone microgranules, and a comparable ODT process would face substantially higher risk. FDA approval of an ANDA does not resolve the patent dispute. A Paragraph IV notice can trigger patent litigation and a statutory 30-month stay under the Hatch-Waxman framework.[4]

Does biosimilar risk apply?

Biosimilar risk is not the relevant competitive pathway for this claim set. The patent claims a small-molecule pharmaceutical composition in an orally disintegrating tablet. The principal regulatory challengers would be ANDA applicants under section 505(j), or potentially 505(b)(2) applicants for products requiring clinical or bridging data.[5]

A biosimilar applicant under the Public Health Service Act would generally not be the expected challenger to this formulation patent.

What litigation, settlement, and licensing issues affect the patent?

No litigation, settlement agreement, license, covenant not to sue, or authorized-generic arrangement is established by the supplied claim text. Those matters depend on docket records, assignment documents, SEC disclosures, licensing announcements, and FDA product records.

The relevant commercial documents would include:

Patent assignments and security interests;
USPTO terminal disclaimers;
ANDA litigation complaints;
Paragraph IV notices;
Consent judgments;
Settlement agreements;
License agreements;
Royalty arrangements; and
Authorized-generic supply agreements.

Without a named active ingredient or marketed product, revenue exposure cannot be assigned to a specific product. The economic value is best characterized as platform optionality across taste-sensitive ODT products rather than exposure to a single identified drug.

What manufacturing and geographic barriers does the patent create?

The patent is a US patent right. It does not, based on the supplied information, establish protection in Europe, Japan, China, Canada, or other jurisdictions. Foreign protection would require corresponding national or regional patent records.

Manufacturing risk is concentrated in process control rather than an expressly claimed manufacturing method. A manufacturer would need to control:

Drug-core particle size;
Coating uniformity;
Ethylcellulose-to-aminoalkyl methacrylate ratio;
Coating weight;
Microgranule size;
Disintegrant and mannitol particle size;
Tablet friability;
Salivary disintegration; and
Acidic dissolution.

The absence of a process claim does not eliminate product-claim risk. A product made by a different process may still infringe if the final composition meets the claimed structural and functional limitations.

How does this patent compare with ordinary ODT and taste-masking patents?

Patent category	Typical protected subject matter	Relationship to US 10,130,580
Conventional ODT patent	Tablet excipients, compression, porosity, disintegration	May overlap with the microgranule and ODT limitations
Taste-masking patent	Coating, matrix, ion exchange, complexation	May overlap with the dual-polymer membrane
Controlled-release patent	Release profile over time	Usually distinct from this immediate-release-oriented claim
Drug-specific formulation patent	Named active ingredient and dosage	Narrower product coverage but potentially stronger commercial relevance
Manufacturing patent	Coating, granulation, or compression process	Separate infringement pathway
US 10,130,580	Combined taste-masked particles and rapidly dispersing ODT microgranules	Combination-platform protection

Key Takeaways

Claim 1 is a narrow combination claim with potentially broad application across active ingredients.
The core limitations are the ethylcellulose/aminoalkyl methacrylate membrane, approximately 50/50 polymer ratio, 10% to 30% coating level, acidic dissolution threshold, and ODT microgranules.
Claims 6 and 10 identify a commercially important mannitol-crospovidone embodiment.
Claims 9 and 11 add performance limitations but may face interpretation or definiteness issues.
The strongest design-arounds change the membrane chemistry, remove the microgranule architecture, or use a non-ODT dosage form.
Orange Book status, patent expiration, Paragraph IV exposure, litigation, settlements, licenses, and revenue impact cannot be determined from the claim language because no active ingredient, patent-term record, or approved product is identified.
Biosimilar competition is not the relevant pathway; ANDA and potentially 505(b)(2) competition are more relevant.
Manufacturing process changes alone may not avoid infringement if the finished dosage form satisfies the product claims.

FAQs

Is US Patent 10,130,580 limited to one drug?

No. The supplied claims do not identify a particular active ingredient. The claims can potentially cover multiple drugs if the products satisfy all structural, compositional, particle-size, dissolution, and dosage-form limitations.

Does using mannitol alone infringe the patent?

Not necessarily. Mannitol is recited in dependent claim 10, but infringement still requires the other limitations of claim 1, including the specified dual-polymer membrane, approximately 50/50 ratio, coating level, dissolution result, and microgranules.

Can a product avoid the patent by using a different disintegrant?

Possibly, but not automatically. Claim 1 requires a disintegrant but does not limit it to the alternatives listed in claim 5. A different disintegrant could still fall within claim 1 if all other limitations are met.

Does a fast-disintegrating tablet necessarily infringe this patent?

No. Rapid disintegration alone is insufficient. The claimed tablet must also contain the specified taste-masked particles and rapidly dispersing microgranules with the required composition and particle-size characteristics.

Is a patent expiration date the same as the date the patent was granted?

No. US utility patent term generally runs from the earliest effective nonprovisional filing date, not from the grant date, subject to statutory adjustments and disclaimers.[3]

References

United States Patent No. 10,130,580, claims 1-12.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
35 U.S.C. § 154.
21 U.S.C. § 355(j); 21 C.F.R. § 314.107.
21 U.S.C. § 355(b)(2), (j); 42 U.S.C. § 262.

Details for Patent: 10,130,580

Summary for Patent: 10,130,580